Combating atherosclerosis with LXR alpha and PPAR alpha agonists: is rational multitargeted polypharmacy the future of therapeutics in complex diseases?
Pediatric and Reproductive Endocrinology Branch, National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA.
Tomoshige
T
Kino
George P
GP
Chrousos
D000818:Animals; D050197:Atherosclerosis / Q000188:drug therapy*; D004268:DNA-Binding Proteins / Q000819:agonists*; D006801:Humans; D000071518:Liver X Receptors; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha / Q000819:agonists*; D019338:Polypharmacy; D018160:Receptors, Cytoplasmic and Nuclear / Q000819:agonists*
D004268:DNA-Binding Proteins; D000071518:Liver X Receptors; C000605213:NR1H3 protein, human; D057093:Orphan Nuclear Receptors; D047493:PPAR alpha; D018160:Receptors, Cytoplasmic and Nuclear